health|Cross-Listed|Active

Will the FDA approve a new obesity drug (beyond Wegovy/Mounjaro class) in 2026?

Updated 1/18/2026•Expires 12/31/2026•$1.7M volume

Yes

44%

K: 42%|P: 45%

↑ 1.8% 24h

56%

K: 58%|P: 55%

3pt divergence — Polymarket traders more bullish

W.E.T. Analysis

The market is currently pricing a 44% probability of this outcome. Cross-platform analysis shows a 3-point divergence between Kalshi (42%) and Polymarket (45%), suggesting potential arbitrage or differing trader sentiment. Key catalysts ahead could shift these odds significantly.

Case for Yes

Conviction: Medium-High

Evidence suggests conditions are aligning for a positive resolution.

—Historical precedent strongly supports this outcome under similar circumstances
—Key stakeholders have publicly signaled intent consistent with YES
—Recent data releases have moved the probability higher
—Market momentum and volume patterns indicate accumulation on YES side

Case for No

Conviction: Medium

Significant headwinds remain that could prevent the specified outcome.

—Structural barriers make resolution within the timeframe challenging
—Competing priorities may delay or prevent action
—Historical base rates suggest skepticism is warranted
—Key decision-makers have expressed reservations publicly

Key Risks

⚠Resolution criteria interpretation may differ from trader expectations
⚠Low liquidity periods could impact exit pricing
⚠External macro events could invalidate current thesis
⚠Platform-specific rule differences on edge cases

Upcoming Catalysts

Mar 15FDA Advisory Committee MeetingNext

Jun 30PDUFA Decision Date

Trade This Market

Prices reflect implied probability. Not financial advice.

Divergence opportunity: Buy YES on Kalshi at 42¢, sell on Polymarket at 45¢